Quest Diagnostics (DGX) Beats Q1 2026 Estimates, Raises Full-Year Guidance

Recent Developments

Quest Diagnostics Incorporated (NYSE: DGX) reported first-quarter 2026 results on April 21, 2026, exceeding Wall Street expectations on both the top and bottom lines. According to the company's earnings release, revenue for the quarter ended March 31, 2026 came in at $2,895 million ($2.90 billion), compared to $2,652 million in the prior-year period — a year-on-year increase of 9.2%.

On the earnings side, Quest Diagnostics posted a non-GAAP profit of $2.50 per share, which was 5.6% above the analyst consensus estimate, according to Yahoo Finance. The company also raised its full-year revenue guidance to a midpoint of $11.84 billion, coming in 0.7% above what analysts had projected ahead of the report.

The combination of a revenue beat, an earnings beat, and upward guidance revision signals that Quest Diagnostics is executing well on both volume growth and cost discipline heading into the remainder of 2026.

Financial Snapshot

Quest Diagnostics shares are trading at $196.31, up $1.29 or 0.66% on the day. The previous close was $195.02. Over the past 52 weeks, the stock has traded between $160.02 and $213.50.

First-quarter revenue of $2.90 billion represented the strongest recent comparable, with the prior-year quarter recording $2.65 billion. The non-GAAP EPS of $2.50 cleared the consensus bar by more than five percent, according to data cited by Yahoo Finance.

Full-year guidance of $11.84 billion at the midpoint modestly exceeded the analyst consensus, providing a forward revenue target that reflects management's confidence in continued demand across its diagnostics network.

Wall Street View

Analyst sentiment on Quest Diagnostics remains broadly constructive. As of the latest consensus recorded on April 1, 2026, the breakdown across 24 analyst ratings is as follows: 6 Strong Buy, 7 Buy, 11 Hold, 0 Sell, and 0 Strong Sell. This distribution is unchanged from the prior period recorded on March 1, 2026, indicating stable sentiment heading into the earnings release. Individual price target data is not available at this time.

The absence of any sell-side Sell or Strong Sell ratings reflects a degree of confidence in Quest Diagnostics' business model and near-term outlook, even as a plurality of analysts maintain a neutral Hold stance.

Key Takeaways

• Quest Diagnostics reported Q1 2026 revenue of $2.90 billion, up 9.2% year-on-year, ahead of Wall Street estimates.
• Non-GAAP EPS of $2.50 came in 5.6% above the analyst consensus, according to Yahoo Finance.
• The company raised full-year 2026 revenue guidance to a midpoint of $11.84 billion, 0.7% above prior analyst expectations.
• Analyst consensus stands at 13 Buy or Strong Buy ratings versus 11 Hold and 0 Sell ratings across 24 tracked analysts.